Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Anbio Biotechnology has announced two significant product launches to address global disease outbreaks. The company introduced a Chikungunya IgM/IgG Rapid Test for detecting Chikungunya fever antibodies in human samples, addressing the rising cases in tropical regions.
Additionally, Anbio launched the AP-100 Ultra-Fast PCR system, a revolutionary point-of-care diagnostic tool that delivers results in 15 minutes. The compact 668g device features an extraction-free workflow and covers multiple pathogens including COVID-19, Flu A/B, RSV, MP, and ADV. The company plans to expand its testing capabilities to include tuberculosis and HPV diagnostics.
Anbio Biotechnology ha annunciato il lancio di due prodotti importanti per far fronte alle epidemie globali. L'azienda ha presentato un test rapido IgM/IgG per Chikungunya per rilevare gli anticorpi della febbre da Chikungunya nei campioni umani, rispondendo all'aumento dei casi nelle regioni tropicali.
Inoltre, Anbio ha lanciato il sistema PCR ultra-rapido AP-100, uno strumento diagnostico point-of-care rivoluzionario che fornisce risultati in 15 minuti. Il compatto dispositivo da 668 g presenta un flusso di lavoro senza estrazione e rileva pi霉 patogeni tra cui COVID-19, influenza A/B, RSV, MP e ADV. L'azienda prevede di ampliare le capacit脿 di test includendo diagnostiche per tubercolosi e HPV.
Anbio Biotechnology ha anunciado dos lanzamientos de productos importantes para hacer frente a brotes de enfermedades a nivel mundial. La compa帽铆a present贸 una prueba r谩pida IgM/IgG para Chikungunya para detectar anticuerpos de la fiebre por Chikungunya en muestras humanas, ante el aumento de casos en regiones tropicales.
Adem谩s, Anbio lanz贸 el sistema PCR ultrarr谩pido AP-100, una revolucionaria herramienta diagn贸stica point-of-care que ofrece resultados en 15 minutos. El dispositivo compacto de 668 g cuenta con un flujo de trabajo sin extracci贸n y detecta m煤ltiples pat贸genos, incluidos COVID-19, gripe A/B, VSR, MP y ADV. La compa帽铆a planea ampliar sus capacidades de prueba para incluir diagn贸sticos de tuberculosis y VPH.
Anbio Biotechnology臧� 鞝� 靹戈硠 歆堧硲 氚滌儩鞐� 雽�鞚戫晿旮� 鞙勴暣 霊� 臧�歆� 欤检殧 鞝滍拡鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚戈皠 鞁滊鞐愳劀 旃橃郡甑媹鞎� 鞐� 頃泊毳� 瓴�於滍晿電� 旃橃郡甑媹鞎� IgM/IgG 鞁犾啀瓴�靷�毳� 靹犽炒鞓�鞙茧┌, 鞐措寑 歆�鞐棎靹� 歃濌皜頃橂姅 頇橃瀽 氚滌儩鞐� 雽�鞚戫暕雼堧嫟.
霕愴暅 Anbio電� AP-100 齑堦碃靻� PCR 鞁滌姢韰�鞚� 於滌嫓頄堧姅雿�, 鞚措姅 15攵� 毵岇棎 瓴瓣臣毳� 鞝滉车頃橂姅 順侅嫚鞝侅澑 順勳灔 歆勲嫧 鞛レ箻鞛呺媹雼�. 靻岉槙 668g 旮瓣赴電� 於旍稖 雼硠臧� 鞐嗠姅 鞗岉伂頂岆毳� 韸轨鞙茧 頃橂┌, COVID-19, 霃呹皭 A/B, RSV, MP 氚� ADV 霌� 鞐煬 氤戩洂觳措ゼ 瓴�於滍暕雼堧嫟. 須岇偓電� 瓴绊暤 氚� HPV 歆勲嫧鞙茧 瓴�靷� 氩旍渼毳� 頇曤寑頃� 瓿勴殟鞛呺媹雼�.
Anbio Biotechnology a annonc茅 deux lancements de produits importants pour faire face aux 茅pid茅mies mondiales. L'entreprise a pr茅sent茅 un test rapide IgM/IgG pour le chikungunya permettant de d茅tecter les anticorps de la fi猫vre chikungunya dans des 茅chantillons humains, en r茅ponse 脿 l'augmentation des cas dans les r茅gions tropicales.
De plus, Anbio a lanc茅 le syst猫me PCR ultra-rapide AP-100, un outil de diagnostic point-of-care r茅volutionnaire qui fournit des r茅sultats en 15 minutes. L'appareil compact de 668 g dispose d'un flux de travail sans extraction et couvre plusieurs agents pathog猫nes, dont COVID-19, grippe A/B, VRS, MP et ADV. L'entreprise pr茅voit d'茅tendre ses capacit茅s de test pour inclure les diagnostics de tuberculose et du HPV.
Anbio Biotechnology hat zwei bedeutende Produktvorstellungen angek眉ndigt, um globalen Krankheitsausbr眉chen zu begegnen. Das Unternehmen stellte einen Chikungunya IgM/IgG Schnelltest zur Erkennung von Antik枚rpern gegen das Chikungunya-Fieber in humanen Proben vor und adressiert damit die steigenden Fallzahlen in tropischen Regionen.
Au脽erdem brachte Anbio das AP-100 Ultra-Fast PCR-System auf den Markt, ein revolution盲res Point-of-Care-Diagnoseger盲t, das Ergebnisse in 15 Minuten liefert. Das kompakte 668 g Ger盲t verf眉gt 眉ber einen extraktionsfreien Arbeitsablauf und deckt mehrere Erreger ab, darunter COVID-19, Influenza A/B, RSV, MP und ADV. Das Unternehmen plant, seine Testkapazit盲ten auf Tuberkulose- und HPV-Diagnostik zu erweitern.
- Launch of innovative Chikungunya IgM/IgG Rapid Test for emerging outbreak detection
- Introduction of AP-100 Ultra-Fast PCR system with 15-minute result time
- Extraction-free workflow reduces complexity and eliminates hazardous reagents
- Planned expansion of testing capabilities to include TB and HPV diagnostics
- None.
Insights
Anbio's dual product launch strengthens infectious disease diagnostics with rapid Chikungunya testing and breakthrough 15-minute PCR technology.
Anbio Biotechnology has strategically expanded its diagnostic portfolio with two significant launches targeting critical needs in infectious disease management. The new Chikungunya IgM/IgG Rapid Test addresses the growing threat of this mosquito-borne disease by enabling qualitative antibody detection in various sample types, crucial for regions experiencing outbreaks.
More technologically disruptive is the AP-100 Ultra-Fast PCR system, which represents a potential paradigm shift in molecular diagnostics. The system's 15-minute turnaround time from raw sample to result dramatically improves on traditional PCR workflows that typically require hours. Its extraction-free methodology eliminates significant complexity barriers that have historically confined PCR testing to centralized laboratories.
The technical specifications鈥攑articularly the 668g weight and extraction-free workflow鈥攑osition this device for deployment across diverse healthcare settings, from remote clinics to emergency departments. This addresses a fundamental gap in diagnostic capacity during outbreaks when laboratory infrastructure becomes overwhelmed.
The platform's flexibility for expansion beyond respiratory pathogens to include TB and HPV testing suggests a broader commercial strategy targeting both acute outbreak response and routine disease management. This dual-purpose approach increases market potential and sustainability beyond pandemic-driven demand cycles that have historically created boom-bust scenarios for diagnostic manufacturers.
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical.
The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio鈥檚 infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks.
In parallel, Anbio is advancing the boundaries of decentralized molecular diagnostics with the launch of its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care.
鈥淥utbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy,鈥� said Michael Lau, CEO of Anbio Biotechnology.
The AP-100 utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction. Its integrated design streamlines sample-to-result workflows, making it well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments.
Key highlights:
- 15-minute PCR results from raw sample to answer
- Extraction-free workflow with no hazardous reagents
- Compact 668g device for mobile or near-patient testing
- Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV
- Lab-comparable accuracy validated against mainstream PCR platforms
While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform. In line with its global infectious disease strategy, Anbio is expanding the assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV), extending its role from rapid outbreak response to sustained disease management.
鈥淲hether it鈥檚 vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat,鈥� Lau added.
With its combination of speed, mobility, and lab-grade precision, Anbio鈥檚 new-generation POCT PCR system strengthens healthcare capacity in both well-resourced and resource-limited settings, advancing global preparedness for infectious disease threats.
About Anbio Biotechnology
Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide.
For more information about Anbio Biotechnology, follow us for the latest news and updates.
Contact: [email protected]
FAQ
What are the key features of Anbio's new AP-100 Ultra-Fast PCR system?
What types of samples can be tested with Anbio's Chikungunya Rapid Test?
What new diseases will Anbio's AP-100 PCR system test for in the future?
How does Anbio's AP-100 PCR system improve upon traditional PCR testing?
